Abstract
The forms of cytochrome P450 involved in the stereoselectiveS-oxidation of flosequinan [(±)-7-fluoro-1-methyl-3-methylsulfinyl-4-quinolone] were investigated in vitro using liver microsomes from rats and humans. Rat liver microsomes supplemented with NADPH catalyzed the four different S-oxidations, which were from flosequinan sulfide (FS; 7-fluoro-1-methyl-3-methylthio-4-quinolone) to R(+)- and S(−)-flosequinan (R-FSO andS-FSO, respectively) and from R-FSO andS-FSO to flosequinan sulfone (FSO2; 7-fluoro-1-methyl-3-methylsulfonyl-4-quinolone). The activities of all the S-oxidases in liver microsomes from male rats were higher than those from female rats. The activities of theS-oxidases measured at a high substrate concentration (1 mM) were induced by treatment of rats with phenobarbital and dexamethasone. Treatment of rats with 3-methylcholanthrene also induced the activities, but only at a low substrate concentration (50 μM), except for the S-oxidase catalyzing the reaction from FS toR-FSO. Enzymes induced by clofibrate and ethanol were not involved in the oxidations at a low substrate concentration. The activities of S-oxidases were correlated with the contents of cytochrome P450 (CYP)3A enzymes. Anti-CYP3A2 antisera inhibited the activities of the S-oxidases catalyzing the reactions from FS to R-FSO (40%) and to S-FSO (60%) at the high substrate concentration and inhibited the activities of theS-oxidases, thus catalyzing reactions fromR-FSO and S-FSO to FSO2 (70%) at both high and low substrate concentrations. These results suggest that CYP3A is the major enzyme involved in all S-oxidation pathways in flosequinan metabolism in rats. On the other hand, except for the S-oxidation of FS to R-FSO, the rates of the other three S-oxidations by liver microsomes from 30 individual humans correlated highly with each other, suggesting that the same enzyme would be involved in the three S-oxidations. Anti-CYP3A2 antisera inhibited the activities of all theS-oxidases in human liver microsomes ranging from 40 to 80%, suggesting that CYP3A is also involved in all of theS-oxidations of flosequinan in humans.
Footnotes
-
Send reprint requests to: Dr. Tetsuya Kamataki, Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido University, N12W6, Sapporo 060, Japan.
-
A part of this study was supported by a Grant-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan.
-
↵2 E. Kashiyama et al., manuscript in preparation.
- Abbreviations used are::
- R-FSO
- R-(+)-flosequinan
- S-FSO
- S-(−)-flosequinan
- FSO2
- flosequinan sulfone
- FS
- flosequinan sulfide
- P450
- cytochrome P450
- FMO
- flavin-containing monooxygenase
- FSO
- flosequinan
- PB
- phenobarbital
- 3-MC
- 3-methylcholanthrene
- DEX
- dexamethasone
- CF
- clofibrate
- EtOH
- ethanol
- GS
- generating system
- CYP
- cytochrome P450
- Received November 27, 1996.
- Accepted March 7, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|